Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Development of new antibiotics is 'stagnant'
Fri June 24th - Work to develop new antibiotics is ‘stagnant’ and does not meet global needs, a new report from the World Health Organization has warned. More
COVID-19 vaccines 'prevented 20 million deaths' in first year
Fri June 24th - In the first year of the vaccination programme, COVID-19 vaccines prevented about 20 million deaths globally, according to an analysis published today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Researchers unveil new pain relief hope

Wednesday February 7th, 2018

A study of the immune system has revealed a “totally novel” mechanism for pain relief, according to Spanish researchers.

Professor Enrique Cobos del Moral and colleagues at the University of Granada, Spain, carried out tests on mice exposed to pressure and heat. They found that a very small protein present in neurons, the sigma-1 receptor, can affect opioid receptors.

Professor Cobos del Moral said: "We present a totally novel pain relief mechanism, based on maximising the analgesic potential of the immune system cells, and which could have important therapeutic applications in patients with pain of inflammatory origin.”

The team reported recently in Proceedings of the National Academy of Sciences that sigma-1 receptor blockers "are capable of increasing the effect of endogenous opioid peptides produced by leukocytes, so that these cells relieve pain instead of producing it when they are in the inflamed tissue.”

They added: "New pain medications with novel mechanisms of action are needed.

“Here we show that sigma-1 antagonism decreases inflammatory pain hypersensitivity by enhancing the actions of endogenous opioid peptides produced by leukocytes in mice.

"Sigma-1 antagonism results in opioid analgesia only at the inflamed site, where immune cells naturally accumulate. This mechanism, which maximises the analgesic potential of immune cells in painful inflamed sites, differs from that of conventional analgesics."

The team believe this represents a totally new pain relief mechanism which could have important therapeutic applications. They are already collaborating with pharmaceutical companies and another research team in Austria.

They conclude: "Our findings suggest that sigma-1 antagonists merit further research as potential agents for the treatment of inflammatory pain."

Tejada, M. A. et al. Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice. Proceedings of the National Academy of Sciences August 2017; doi: 10.1073/pnas.1620068114 [abstract]

Tags: Europe | Pain Relief | Pharmaceuticals

Printer friendly page Printer friendly page


1At 08/02/2018 06:07pm David Kelly wrote

Would you like to write a piece about this to be included on our website; patients suffering from Chronic Pain would I am sure find it very interesting.Many Thanks, David Kelly see: to see what we have achieved so far

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)